Short answer
Biomarin Pharmaceutical Inc (BMRN) filed an 8-K current report with the SEC on September 1, 2026 reporting Item 8.01 (Other Events). BioMarin completed its acquisition of Alesta Therapeutics on August 31, 2026.
Biomarin Pharmaceutical Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- BioMarin completed its acquisition of Alesta Therapeutics on August 31, 2026
- Alesta is now a wholly owned BioMarin subsidiary
- Transaction execution shifts Alesta from external asset to BioMarin-controlled operations
- Investors should monitor subsequent filings for purchase consideration and financial statement impacts
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Biomarin Pharmaceutical Inc 8-K filings
Get the next BMRN 8-K as it lands
Follow BMRN for push alerts, or ask the research agent what this filing means.